510 Nedosiran, another RNAi drug developed by Dicerna Pharmaceuticals that targets LDHA, is currently being evaluated for its efficacy in reducing oxalate production
Nn ung nhiu nc trong ngy chuyn ha tt
[21] [22] [23] FOXO4 activates the cell cycle dependent kinase inhibitor, P27, which in turn prevents tumors from progressing into G1
As a skincare ingredient, it is revered for its ability to brighten and enhance the overall appearance of the skin
doi: 10.3389/fendo.2011.00102 89 KuoLEKitlinskaJBTilanJULiLBakerSBJohnsonMDet al
*Correspondence: Qiuxin Chen, [email protected] Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers